Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPRF | P10586 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406800 | 0.93 | PTPN1 (0.41) | PTPN1HTR2ACHRM2CHRM4CHRM5 | |
| SCHEMBL6403734 | 0.91 | PTPN1 (0.42) | PTPN1PTPRCPTPRFCDC25BBCHE | |
| SCHEMBL6401023 | 0.91 | PTPN1 (0.42) | PTPN1PTPRCPTPRFCDC25BBCHE | |
| SCHEMBL6406592 | 0.74 | MEN1 (0.35) | CYP1A2CYP2D6 | |
| SCHEMBL6406806 | 0.70 | CHRM2 (0.31) | PTPN1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6401846 | 0.69 | PTPN1 (0.40) | PTPN1HTR2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6401889 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL6408809 | 0.69 | PTPN1 (0.30) | PTPN1 | |
| SCHEMBL6400706 | 0.68 | PTPN1 (0.33) | PTPN1PTPRCPTPRFCDC25BBCHE | |
| SCHEMBL6408816 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844288-B2 | Process for the preparation of ligands for metallogene catalysts | BASELL POLYOLEFINE GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | EQUISTAR CHEMICALS, LP | 2003-08-21 | — | — | US | disclosed |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | RESCONI LUIGI (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6423796-B1 | COORDINATION CATALYST | BASEL TECHNOLOGY COMPANY BV (NL) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | MACF1, SDC1, SDC2 | PTPN1 2634/4885HTR2A 4160/4885CHRM2 2954/4885 |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | SDC1, SDC2, SDC4 | PTPN1 2663/4885HTR2A 3843/4885CHRM2 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.